In this study, we analysed the levels of circulating CD137+ T cells in (R/M) HNSCC patients who underwent pembrolizumab treatment as a first-line therapy, alone or in combination with platinum-based chemotherapy. Here, TNFRSF9 is linked to head and neck squamous cell carcinoma.